The word "doper" hit the LetsRun thread before Mike McKnight finished his Instagram statement. Within hours of the Utah ultrarunner's July 2026 podcast admission that he used BPC-157 to cancel a scheduled back surgery, the forum had sorted into camps: cheat, patient, or symptom of a broken testing regime. On Reddit's r/ultrarunning board, one commenter noted that BPC-157 and similar peptides "are not approved by the FDA because no one has paid for the trials yet," framing the peptide less as a banned substance than as an orphaned molecule circulating through wellness networks while regulators stalled. McKnight himself called the injection his "Hail Mary before getting surgery." That phrase became the thread's gravitational center.
McKnight, a decorated 200-mile specialist and running coach, disclosed the peptide use first on Cam Hanes' podcast, then in a longer written statement. He said he herniated a disc after slipping on laundry detergent 24 hours after finishing Cocodona 250 in 2025, spent months in severe pain, and scheduled surgery. A nurse visited his home, explained the peptide, and recommended a daily dose. McKnight reported "major improvements by the end of the first week" and cancelled the operation. He then set a course record at the Arizona Monster 300 that spring and finished 13th at Cocodona 250 in May. Canadian Running Magazine reported the disclosure on July 24, 2026.
USADA prohibits BPC-157 under WADA's S0 category, which covers substances not approved for human clinical use by any global regulatory authority. The ban applies at all times, in and out of competition. McKnight stated he did not know the peptide was prohibited, then added he would not reverse the decision: "This decision kept me from having to have back surgery. This decision made it so I could walk and start doing something that has been a part of my life for almost 15 years."
Figure 1: Biomedical laboratory assay and analytical documentation.
The forum thread that preceded the sanction
The community had already been circling this fight before McKnight spoke. Hanes, 58, disclosed his own BPC-157 use after Cocodona 250 and ran a 2:39 marathon at Eugene—a 13-minute personal best. Elite ultrarunner Sage Canaday filed a tip with USADA alleging Hanes had promoted the peptide publicly. A LetsRun poster searched the USADA sanctions database and surfaced prior BPC-157 penalties: two four-month bans in fencing, three one-year bans in triathlon. No ultra-running precedent exists. The thread's implication was plain—McKnight and Hanes occupy a sport where enforcement arrives through podcast confessions and rival athletes' tips rather than finish-line urine samples.
The language on those boards matters. "Wellness" and "recovery" appear in the same sentences as "banned" and "S0," collapsing the distance between a gym-community self-experiment and a WADA violation. USADA flagged the peptide on X, noting BPC-157 is "making its way into wellness and anti-aging treatments" while remaining prohibited. The agency's framing treats the peptide as a doping risk. The Reddit commenter's framing treats it as an underfunded therapeutic candidate. Neither framing resolves the other.
One day before McKnight's statement went live, the FDA's Pharmacy Compounding Advisory Committee met July 23–24 in Silver Spring and voted 8–6, with one abstention, to recommend BPC-157, KPV, and TB-500 for the Section 503A bulks list, which would permit compounding pharmacies to prepare them. PharmExec reported the vote breakdown. The Focal Points covered the session and described it as the committee's "most consequential peptide meeting in years." The recommendation does not constitute drug approval; BPC-157 remains unapproved for human clinical use. But the vote places a U.S. regulatory body one step closer to permitting pharmacy preparation of a molecule WADA bans at all times. For athletes obtaining the peptide through home-visiting nurses or online "research use only" vendors rather than licensed prescribers, the regulatory ground is shifting beneath an active anti-doping case.
McKnight addressed the Therapeutic Use Exemption question directly. He said he completed months of physical therapy, saw a chiropractor, and consulted holistic practitioners before the peptide entered the picture. "I don't understand how there is anything on that list that you can't get a TUE for," he said. WADA's TUE framework does allow exemptions, but S0 substances lack any recognized therapeutic protocol, which means there is no approved medical indication to document in an application.
Coaching inside the ambiguity
McKnight's coaching practice now sits in the gap between his own experience and the rulebook he violated. Asked how he would respond if an athlete he trains inquired about BPC-157, he told Canadian Running Magazine he was unsure: "The human side of me would want to tell them my experience and tell them to look into it. But, the safe side of me would want to not say anything at all." The question of whether peptides are banned under NCAA rules has also resurfaced after a separate incident involving Iowa cross-country athletes surfaced on the Slowtwitch forum, pushing the conversation from professional ultra-running into youth and collegiate programs.
USADA has not announced whether it will open a formal proceeding against McKnight. The agency's existing BPC-157 sanctions in other sports range from four months to one year, but no trail-racing precedent constrains the outcome. The FDA's final rulemaking decision on compounding access remains pending. McKnight's next race entry, his coaching roster, and the question of whether USADA treats a podcast admission as sufficient evidence for a violation all depend on that next administrative step.
Related Peptides Agora coverage examines ghrp peptides.
